Robles BioCeutics, a regenerative dermatology company founded by Maria Robles, recently announced the submission of patent application #63/695,813, titled "Activated Stem Cell Derived Products for Stimulation of Skin Regeneration." The application was filed by Knobbe Martens and covers the composition of matter as well as the production methodologies for stem cell-derived components in the company's Glowselle regenerative cream.
Related: Editor's Picks: Plant- vs. Mammalian-Derived Exosomes
Rather than isolate components from stems cell in a resting state, the company isolates components from “activated” stem cells. This break from utilizing traditional adipose-derived stem cells has proven beneficial in significantly amplifying the stem cell-derived components’ regenerative activity. Per Robles BioCeutics, this toll-like receptor-based stem cell stimulation has shown up to 10 times higher production of therapeutic exosomes and growth factors compared to standard adipose-derived stem cells. The company's flagship product, Glowselle, replicates an injury signal in the lab, activating the body's own stem cells to promote the natural production of essential growth factors and exosomes. 
Maria Robles, President and CEO of Robles BioCeuticsPhoto courtesy of Robles BioCeutics
"This patent filing reflects the passion and effort our team has put into developing something we're very proud of and believe will have a real impact," said Maria Robles, President and CEO of Robles BioCeutics. "Glowselle is more than just an anti-aging cream; it represents a new paradigm in regenerative dermatology, and this patent is a crucial step in protecting our innovative approach as we continue to expand our product offerings."
In an effort to advance research into the molecular mechanisms behind its patent-pending Glowselle skin cream Robles BioCeutics has now entered into a new collaboration with BioCentrium, per the company. Specifically, the partnership will focus on examining how Glowselle facilitates its regenerative effects on aged and photodamaged skin.
"Robles BioCeutics brings a refreshing, science-first approach to the stem cell cosmetic space, which is often dominated by marketing over substance," said Emma Lin, President of BioCentrium. "We've already seen exciting data from Maria Robles and her team, and we look forward to delving deeper into the science behind these results. We aim to publish our findings in a peer-reviewed journal."
BioCentrium will seek to identify and calculate the specific pathways activated by Glowselle treatment using its proprietary cellular and molecular platforms. The collaboration will give BioCentrium an equity interest in the company, however Robles BioCeutics will keep all intellectual property rights obtained through the research.
"Regenerative dermatology holds immense potential for slowing down and even reversing skin aging," said Maria Robles, President and CEO of Robles BioCeutics. "Our priority is to understand the cellular mechanisms behind Glowselle's efficacy, ensuring its potency, safety, and compatibility with other products. We're excited to collaborate with BioCentrium to expand the scientific understanding of this novel skincare approach."
